

DAFTAR PUSTAKA

- Abdullah, A. *et al.* (2017) ‘Assessment of Knowledge and Attitude and Practice of Parents about Immunization in Jeddah City, 2017’, *The Egyptian Journal of Hospital Medicine*, 69(7). doi: 10.12816/0042589.
- Aini, N.- and Purwasari, M. D. (2021) ‘Sikap dan Perilaku Pencegahan Covid-19 di Desa Kemuningsari Kidul Kabupaten Jember’, *Jurnal Kesehatan*. Politeknik Negeri Jember, 8(3), pp. 171–177. doi: 10.25047/J-KES.V8I3.176.
- Al-Marshoudi, S. *et al.* (2021) ‘Knowledge, Attitudes, and Practices (KAP) toward the COVID-19 Vaccine in Oman: A Pre-Campaign Cross-Sectional Study’, *Vaccines*. MDPI AG, 9(6), p. 602. doi: 10.3390/vaccines9060602.
- Alqudeimat, Y. *et al.* (2019) ‘Acceptance of a COVID-19 Vaccine and Its Related Determinants among the General Adult Population in Kuwait Highlights of the Study Alqudeimat et al’. doi: 10.1159/000514636.
- Ardiningsih, N. N. A. and Kardiwinata, M. P. (2021) ‘Persepsi Masyarakat Terhadap Penerimaan Vaksinasi COVID-19 di Kabupaten Karangasem : Sebuah Studi Cross-Sectional’, *Jurnal Riset Kesehatan Nasional*, 5(2).
- Armitage, C. J. and Conner, M. (2000) ‘Social cognition models and health behaviour: A structured review’, *Psychology and Health*. Routledge, pp. 173–189. doi: 10.1080/08870440008400299.
- Azim, L. O. L., Rahman and Lade Albar Khalza (2021) ‘PENERIMAAN MASYARAKAT TERHADAP VAKSIN COVID-19 BERDASARKAN TEORI HEALTH BELIEF MODEL DI KECAMATAN POASIA KOTA KENDARI’, *HOSPITAL MAJAPAHIT*, 13(2). Available at: <http://ejournal.stikesmajapahit.ac.id/>.
- Betsch, C., Bohm, R. and Korn, L. (2013) ‘Inviting free-riders or appealing to prosocial behavior? Game-theoretical reflections on communicating herd immunity in vaccine advocacy’, *Health Psychology*, 32(9), pp. 978–985. doi: 10.1037/A0031590.
- Bish, A. *et al.* (2011) ‘Factors associated with uptake of vaccination against pandemic influenza: a systematic review’, *Vaccine*. Vaccine, 29(38), pp. 6472–6484. doi: 10.1016/J.VACCINE.2011.06.107.
- BPS (2020) *Rinngkasan Eksekutif pengeluaran dan Konsumsi Penduduk Indoensia*. Available at: <https://www.bps.go.id/>.
- Brewer, N. T. *et al.* (2007) ‘Meta-analysis of the relationship between risk perception

- and health behavior: The example of vaccination', *Health Psychology*, 26(2), pp. 136–145. doi: 10.1037/0278-6133.26.2.136.
- Brunson, E. K. (2013) 'The impact of social networks on parents' vaccination decisions', *Pediatrics*. Pediatrics, 131(5). doi: 10.1542/PEDS.2012-2452.
- Cao, Z. J., Chen, Y. and Wang, S. M. (2014) 'Health belief model based evaluation of school health education programme for injury prevention among high school students in the community context', *BMC Public Health*, 14(1). doi: 10.1186/1471-2458-14-26.
- CDC (2021) *Benefits of Getting a COVID-19 Vaccine*. Available at: <https://www.cdc.gov/>.
- Cellule d'Analyse en Sciences Sociales (CASS) (2020) 'Rekomendasi Program Kemanusiaan untuk COVID-19 Berdasarkan Bukti Ilmu Sosial dari Respon Wabah Ebola: Social Science Support for COVID-19: Lessons Learned Brief 3 Humanitarian programme recommendations for COVID-19 based on social sciences evidence from t'. Available at: <https://www.unicef.org/>.
- Chen, N. *et al.* (2020) 'Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study', *The Lancet*, 395, pp. 507–513. doi: 10.1016/S0140-6736(20)30211-7.
- Coe, A. B. *et al.* (2012) 'View of The use of the health belief model to assess predictors of intent to receive the novel (2009) H1N1 influenza vaccine', *Inov Pharm*, 3(2). Available at: <https://pubs.lib.umn.edu/>.
- Community Preventive Services Task Force (2016) 'Increasing Appropriate Vaccination: Home Visits to Increase Vaccination Rates'. Available at: <https://www.thecommunityguide.org/>.
- Conner, M. (2010) 'Cognitive Determinants of Health Behavior', in *Handbook of Behavioral Medicine*. Springer New York, pp. 19–30. doi: 10.1007/978-0-387-09488-5_2.
- Conner, M. and Paul Norman (2015) *HEALTH BEHAVIOUR Research and Practice with Social Cognition Models Third Edition*. New York: Open University Press.
- Dinas Kesehatan Kota Palopo (2021) *LAPORAN REKAPITULASI HASIL PELAKSANAAN IMUNISASI COVID-19*. Palopo.
- Dinkes Kota Palopo (2021) *Pemantauan Covid Kota Palopo*. Palopo.
- Direktur Jenderal Pencegahan dan Pengendalian Penyakit (2021) *PETUNJUK*

TEKNIS PELAKSANAAN VAKSINASI DALAM RANGKA PENANGGULANGAN PANDEMI CORONA VIRUS DISEASE 2019 (COVID-19). Kementerian Kesehatan .

- Dirjen P2P (2021) *PETUNJUK TEKNIS PELAKSANAAN VAKSINASI DALAM RANGKA PENANGGULANGAN PANDEMI CORONA VIRUS DISEASE 2019 (COVID-19)*, Kementerian Kesehatan . Kementerian Kesehatan.
- Ge, H. *et al.* (2020) ‘The epidemiology and clinical information about COVID-19’, *European Journal of Clinical Microbiology & Infectious Diseases*. doi: 10.1007/s10096-020-03874-z.
- Glanz, K., Rimer, B. K. and Viswanath, K. (2015) *Health Behavior: Theory, Research, and Practice*. Hoboken: Jossey-Bass.
- Guan, W. *et al.* (2020) ‘Clinical Characteristics of Coronavirus Disease 2019 in China’, *New England Journal of Medicine*. Massachusetts Medical Society, 382(18), pp. 1708–1720. doi: 10.1056/NEJMoa2002032.
- Harrison, J. A., Mullen, P. D. and Green, L. W. (1992) ‘A meta-analysis of studies of the health belief model with adults’, *Health Education Research*. Health Educ Res, 7(1), pp. 107–116. doi: 10.1093/her/7.1.107.
- Hasibuan, E. A. and Sinambela, M. (2020) ‘ANALISI FAKTOR YANG BERHUBUNGAN DENGAN PENERIMAAN IBU TERHADAP IMUNISASI MR PADA MURID SEKOLAH DASAR’, *Jurnal Ilmiah Kebidanan dan Kespro*, 2(2), pp. 45–52. Available at: <http://ejournal.delihu.ac.id/>.
- Hayden, J. (2009) *Introduction to Health Behavior Theory*. United States: Bartlett Publisher, LLC.
- Hossain, M. B. *et al.* (2021) ‘Health Belief Model, Theory of Planned Behavior, or Psychological Antecedents: What Predicts COVID-19 Vaccine Hesitancy Better Among the Bangladeshi Adults?’, *Frontiers in Public Health*. Frontiers Media S.A., 9, p. 1172. doi: 10.3389/FPUBH.2021.711066/BIBTEX.
- Huang, C. *et al.* (2020) ‘Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China’, *The Lancet*. Lancet Publishing Group, 395(10223), pp. 497–506. doi: 10.1016/S0140-6736(20)30183-5.
- Irwan (2017) *Etika dan Perilaku Kesehatan*. Gorontalo: CV Absolute Media.
- Janz, N. K. *et al.* (1984) *The Health Belief Model: A Decade Later reprint requests to*. John Wiley and Sons Ltd.

- Kemenkes (2021) *Vaksin Dashboard*. Available at: <https://vaksin.kemkes.go.id/#/vaccines> (Accessed: 24 June 2021).
- Kementerian Kesehatan RI *et al.* (2020) *Survei Penerimaan Vaksinasi COVID-19 di Indoensia*. Available at: <https://covid19.go.id/>.
- Kementerian Kesehatan RI (2021) *SITUASI TERKINI PERKEMBANGAN NOVEL CORONAVIRUS (COVID-19)*. Jakarta.
- KIPI, K. (2021) *KIPI - Kejadian Ikutan Pasca Imunisasi*. Available at: <https://kipi.covid19.go.id/> (Accessed: 25 June 2021).
- KPCPEN (2021) ‘Paket Advokasi Vaksinasi COVID-19: Lindungi Diri, Lindungi Negara’, in.
- Lauer, S. A. *et al.* (2020) ‘The incubation period of coronavirus disease 2019 (CoVID-19) from publicly reported confirmed cases: Estimation and application’, *Annals of Internal Medicine*. American College of Physicians, 172(9), pp. 577–582. doi: 10.7326/M20-0504.
- Li, Q. *et al.* (2020) ‘Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia’, *New England Journal of Medicine*. Massachusetts Medical Society, 382(13), pp. 1199–1207. doi: 10.1056/nejmoa2001316.
- Lin, Y. *et al.* (2020) ‘Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China’, *PLoS neglected tropical diseases*. NLM (Medline), 14(12), p. e0008961. doi: 10.1371/journal.pntd.0008961.
- Machindra Kudale, A. *et al.* (2020) ‘Acceptance of a COVID-19 Vaccine in Southeast Asia: A Cross-Sectional Study in Indonesia’, *Front. Public Health*, 8, p. 381. doi: 10.3389/fpubh.2020.00381.
- Mahmud, S. *et al.* (2021) ‘Knowledge, beliefs, attitudes and perceived risk about COVID-19 vaccine and determinants of COVID-19 vaccine acceptance in Bangladesh’, *PLOS ONE*. Public Library of Science, 16(9), p. e0257096. doi: 10.1371/JOURNAL.PONE.0257096.
- Malik, A. A. *et al.* (2020) ‘Determinants of COVID-19 vaccine acceptance in the US’, *EClinicalMedicine*. Lancet Publishing Group, 26, p. 100495. doi: 10.1016/j.eclinm.2020.100495.
- Mohamed, N. A. *et al.* (2021) ‘Knowledge, acceptance and perception on COVID-19 vaccine among Malaysians: A web-based survey’, *PLOS ONE*. Edited by E. Sobh. Public Library of Science, 16(8), p. e0256110. doi: 10.1371/JOURNAL.PONE.0256110.

- Nugroho, S. A., Binti Istiqomah; and Rohanisa; (2021) ‘Pengetahuan, Persepsi, dan Perilaku terkait COVID-19 serta Penerimaan terhadap Vaksin COVID-19 pada Masyarakat di Kota Tasikmalaya’, *Jurnal Keperawatan Profesional (JKP)*, 9(2). Available at: <http://etd.repository.ugm.ac.id/>.
- Onder, G., Rezza, G. and Brusaferro, S. (2020) ‘Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy’, *JAMA - Journal of the American Medical Association*. American Medical Association, pp. 1775–1776. doi: 10.1001/jama.2020.4683.
- Onoruoiza, S. I. et al. (2015) ‘Using Health Beliefs Model as an Intervention to Non Compliance with Hypertension Information among Hypertensive Patient’, *IOSR Journal Of Humanities And Social Science (IOSR-JHSS)*, 20(9), pp. 11–16. doi: 10.9790/0837-20951116.
- Puspasari, A. and Achadi, A. (2021) ‘Pendekatan Health Belief Model untuk Menganalisis Penerimaan Vaksinasi Covid-19 Di Indonesia’, *Syntax Literate ; Jurnal Ilmiah Indonesia*, 6(8), pp. 3709–3721. doi: 10.36418/SYNTAX-LITERATE.V6I8.3750.
- Ratnapradipa, K. L. et al. (2017) ‘Freshman Flu Vaccination Behavior and Intention During a Nonpandemic Season’, *Health promotion practice*. Health Promot Pract, 18(5), pp. 662–671. doi: 10.1177/1524839917712731.
- Rutter, D. and Lyn Quine (2005) *Changing Health Behaviour: Intervention and Research with Social Cognition Models*. Edited by D. Rutter and Lyn Quine. New York: Open University Press. Available at: <https://ipfs.io/>.
- Satgas Penanganan COVID-19 (2021a) *Peta Sebaran*. Available at: <https://covid19.go.id/peta-sebaran>.
- Satgas Penanganan COVID-19 (2021b) *Siapa Saja Yang Tidak Boleh Diberi Vaksin COVID-19?* Available at: <https://covid19.go.id/>.
- Schoch-Spana, M. et al. (2021) ‘The public’s role in COVID-19 vaccination: Human-centered recommendations to enhance pandemic vaccine awareness, access, and acceptance in the United States’, *Vaccine*, 39(40). Available at: <https://pubmed.ncbi.nlm.nih.gov/33160755/>.
- Shmueli, L. (2021) ‘Predicting intention to receive COVID-19 vaccine among the general population using the health belief model and the theory of planned behavior model’, *BMC public health*. NLM (Medline), 21(1), p. 804. doi: 10.1186/S12889-021-10816-7/TABLES/4.
- Sookaromdee, P. and Wiwanitkit, V. (2020) ‘Imported cases of 2019-novel

- coronavirus (2019-nCoV) infections in Thailand: Mathematical modelling of the outbreak’, *Asian Pacific Journal of Tropical Medicine*. Wolters Kluwer Medknow Publications, 13(3), pp. 139–140. doi: 10.4103/1995-7645.277516.
- The Lancet Respiratory Medicine (2020) ‘COVID-19 transmission—up in the air’, *The Lancet Respiratory Medicine*. Lancet Publishing Group, p. 1159. doi: 10.1016/S2213-2600(20)30514-2.
- Tsutsui, Y., Benzion, U. and Shahrabani, S. (2012) ‘Economic and behavioral factors in an individual’s decision to take the influenza vaccination in Japan’, *Journal of Socio-Economics*. North-Holland, 41(5), pp. 594–602. doi: 10.1016/j.socloc.2012.05.001.
- UNICEF (2020) *Survei penerimaan vaksin COVID-19 di Indonesia*. Available at: <https://www.unicef.org/>.
- Wang, J. et al. (2020) ‘Acceptance of COVID-19 Vaccination during the COVID-19 Pandemic in China’, *Vaccines*. MDPI AG, 8(3), p. 482. doi: 10.3390/vaccines8030482.
- WHO (2019) *Vaccines and immunization*. Available at: <https://www.who.int/>.
- WHO (2020a) ‘Acceptance and Uptake of COVID-19 Vaccines Who Technical Advisory Group on Behavioural Insights and Sciences for Health’. Available at: <http://apps.who.int/bookorders>.
- WHO (2020b) *Coronavirus disease (COVID-19): How is it transmitted?*, World Health Organization. Available at: <https://www.who.int/news-room/detail/coronavirus-disease-covid-19-how-is-it-transmitted> (Accessed: 26 February 2021).
- WHO (2020c) *Impact of COVID-19 on people’s livelihoods, their health and our food systems*, World Health Organization. Available at: <https://www.who.int/>.
- WHO (2020d) *Virus corona*, World Health Organization. Available at: <https://www.who.int/>.
- WHO (2021) *WHO Coronavirus Disease (COVID-19) Dashboard*. Available at: <https://covid19.who.int/>.
- Wong, L. P. et al. (2020) ‘The use of the health belief model to assess predictors of intent to receive the COVID-19 vaccine and willingness to pay’, *Human vaccines & immunotherapeutics*. Hum Vaccin Immunother, 16(9), pp. 2204–2214. doi: 10.1080/21645515.2020.1790279.
- Wu, Z. and McGoogan, J. M. (2020) ‘Characteristics of and Important Lessons from

- the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention’, *JAMA - Journal of the American Medical Association*. American Medical Association, 323(13), pp. 1239–1242. doi: 10.1001/jama.2020.2648.
- Wulandari, D. *et al.* (2021) ‘Faktor-Faktor yang Berhubungan dengan Persepsi Tenaga Kesehatan Terhadap Vaksin COVID-19 di Puskesmas X Tahun 2020’, *Jurnal Kesehatan Masyarakat (e-Journal)*, 9(September), pp. 660–668.
- Yang, R., Penders, B. and Horstman, K. (2019) ‘Addressing Vaccine Hesitancy in China: A Scoping Review of Chinese Scholarship’, *Vaccines*. MDPI AG, 8(1), p. 2. doi: 10.3390/vaccines8010002.
- Yang, Y. *et al.* (2020) ‘SARS-CoV-2: characteristics and current advances in research’, *Virology Journal*. BioMed Central, p. 117. doi: 10.1186/s12985-020-01369-z.
- Yumna Rizqillah, L. (2021) ‘ANALISIS FAKTOR HEALTH BELIEF MODEL PADA PENERIMAAN VAKSINASI COVID-19’: *Jurnal Medika Hutama*, 3(01 Oktober), pp. 1734–1738. Available at: <https://jurnalmedikahutama.com/>.

LAMPIRAN

Lampiran 1

KUESIONER PENELITIAN

FAKTOR YANG BERHUBUNGAN PENERIMAAN VAKSIN COVID-19

Petunjuk Pengisian Kuesioner

2. Pilihlah jawaban yang sesuai dengan keadaan Anda yang sebenarnya.
3. Jawaban dipilih berdasarkan pikiran dan pengetahuan pribadi, tidak boleh meminta pendapat orang lain ataupun membuka mencari jawaban melalui sumber lain.
4. Pengisian kuesioner memerlukan waktu ± 10 menit.
5. Jawaban yang Anda berikan bersifat rahasia dan hanya akan dipergunakan untuk keperluan penelitian.

| A | PERTANYAAN UMUM | |
|---|--|--|
| 1 | Tanggal Lahir | |
| 2 | Umur | Tahun |
| 3 | Apakah Anda bertempat tinggal di Kota Palopo? | [1] Ya [2] Tidak |
| 4 | Status tempat tinggal | [1] Bersama orang tua [2] Bersama kelurga lain [3] Kost/Rumah Sewa/Kontrak [4] Asrama [5] Lainnya (Sebutkan) |
| 5 | Berapa lama Anda sudah tinggal di Kota Palopo? | [1] < 6 bulan (Lanjut pertanyaan no. 6) [2] ≥ 6 bulan (Lanjut pertanyaan no. 7) |
| 6 | Saya berencana untuk tinggal (menetap atau sementara) di Kota Palopo dalam jangka waktu 6 bulan atau lebih | [1] Ya [2] Tidak |
| 7 | Apakah Anda sudah pernah melakukan vaksinasi COVID-19? | [1] Ya [2] Tidak |

| B | KARAKTERISTIK RESPONDE | |
|---|------------------------|---|
| 1 | Jenis Kelamin | [1] Perempuan [2] Laki-laki |
| 2 | Status Perkawinan | [1] Belum Kawin [2] Kawin [3] Cerai Hidup/Cerai Mati |
| 3 | Pendidikan | [1] Tidak Sekolah [2] Tidak Tamat SD/Sederajat [3] Tamat SD/Sederajat [4] Tamat SMP/Sederajat [5] Tamat SMA/Sederajat |

| | | |
|---|----------------------|---|
| | | [6] Tamat Perguruan Tinggi |
| 4 | Pekerjaan Orang Ayah | <p>[1] PNS/TNI/Polri/BUMN/BUMD [2] Pegawai Swasta [3] Wiraswasta [4] Petani/Buruh Tani [5] Nelayan [6] Buruh/Sopir/Asisten Rumah Tsngga [7] Tidak/Belum Bekerja [8] lainnya (sebutkan)</p> |
| 5 | Pekerjaan Orang Ibu | <p>[1] PNS/TNI/Polri/BUMN/BUMD [2] Pegawai Swasta [3] Wiraswasta [4] Petani/Buruh Tani [5] Nelayan [6] Buruh/Sopir/Asisten Rumah Tsngga [7] Ibu Rumah Tangga [8] Tidak/Belum Bekerja [9] lainnya (sebutkan)</p> |
| 6 | Pendapatan Orang Tua | <p>[1] < Rp 3.310.723 [2] Rp 3.310.723 – Rp 6.621.446 [3] > Rp 6.621.446</p> |

| C | PENGETAHUAN GEJALA, CARA PENULARAN, DAN CARA PENCEGAHAN COVID-19 | | |
|---|---|--------|-----------|
| 1 | Menurut Anda, apakah yang menjadi penyebab COVID-19? | | |
| | 1) Bakteri | [1] Ya | [2] Tidak |
| | 2) Virus | [1] Ya | [2] Tidak |
| | 3) Jamur | [1] Ya | [2] Tidak |
| | 4) Kutukan | [1] Ya | [2] Tidak |
| 2 | Menurut Anda, apa sajakah yang merupakan gejala utama atau yang paling umum terjadi apabila terkena COVID-19? | | |
| | 1) Demam | [1] Ya | [2] Tidak |
| | 2) Batuk | [1] Ya | [2] Tidak |
| | 3) Nyeri Otot dan Sendi | [1] Ya | [2] Tidak |
| | 4) Kelelahan | [1] Ya | [2] Tidak |
| | 5) Sakit Tenggorokan | [1] Ya | [2] Tidak |
| | 6) Sesak Napas | [1] Ya | [2] Tidak |
| | 7) Muntah | [1] Ya | [2] Tidak |
| | 8) Mual | [1] Ya | [2] Tidak |
| | 9) Kehilangan Indera Penciuman (Bau) | [1] Ya | [2] Tidak |
| | 10) Kehilangan Indera Pengecap (Perasa) | [1] Ya | [2] Tidak |

| | | | |
|---|--|--------|-----------|
| | 11) Hidung Tersumbat | [1] Ya | [2] Tidak |
| | 12) Bersin dan Pilek | [1] Ya | [2] Tidak |
| | | | |
| 3 | Menurut Anda, bagaimana cara penularan COVID-19 ? | | |
| | 1) Menyebar melalui droplet atau tetesan pernapasan saat orang yang terinfeksi COVID-19 bersin, batuk, atau berbicara | [1] Ya | [2] Tidak |
| | 2) Menyentuh mata, hidung, atau mulut setelah menyentuh permukaan yang terkontaminasi virus. | [1] Ya | [2] Tidak |
| | 3) Menyentuh hewan dapat menyebabkan COVID-19 | [1] Ya | [2] Tidak |
| | 4) COVID-19 dapat menular melalui makanan | [1] Ya | [2] Tidak |
| | 5) Berpapasan dengan penderit COVID-19 | [1] Ya | [2] Tidak |
| | 6) COVID-19 menular melalui udara | [1] Ya | [2] Tidak |
| | 7) COVID-19 dapat ditularkan melalui gigitan nyamuk | [1] Ya | [2] Tidak |
| | 8) COVID-19 menular melalui barang atau produksi impor | [1] Ya | [2] Tidak |
| | 9) Menular melalui jarangan 5G | | |
| | | | |
| 4 | Menurut Anda, bagaimana cara mencegah penularan COVID-19? | | |
| | 1) Menjaga jarak dari orang lain minimal 1 meter | [1] Ya | [2] Tidak |
| | 2) Menghindari kontak fisik | [1] Ya | [2] Tidak |
| | 3) Menggunakan masker dengan benar, yaitu dengan menutup hidung, mulut dan dagu | [1] Ya | [2] Tidak |
| | 4) Mengonsumsi bawang putih | [1] Ya | [2] Tidak |
| | 5) Mengonsumsi alkohol | [1] Ya | [2] Tidak |
| | 6) Meminum minyak kayu putih secara langsung maupun dicampur dengan air untuk meredakan gejala COVID-19 | [1] Ya | [2] Tidak |
| | 7) Rutin memberishkan tangan dengan cara mencuci tangan menggunakan sabun dan air mengalir atau menggunakan <i>handsanitizer</i> | [1] Ya | [2] Tidak |
| | 8) Mandi menggunakan air panas | [1] Ya | [2] Tidak |
| | 9) Hindari menyentuh hidung, mulut, dan mata tanpa membersihkan tangan terlebih dahulu | [1] Ya | [2] Tidak |
| | 10) Menggunakan sarung tangan karet | [1] Ya | [2] Tidak |
| | 11) Bersihkan dan disinfeksi permukaan yang sering disentuh, seperti gagang pintu, keran, layar ponsel, dan lainnya. | [1] Ya | [2] Tidak |
| | 12) Menghindari keramaian atau kerumunan | [1] Ya | [2] Tidak |

| | | | |
|---|--|--------|-----------|
| | 13) Melakukan vaksinasi COVID-19 | [1] Ya | [2] Tidak |
| 5 | Di mana biasanya Anda mendapatkan informasi tentang vaksin COVID-19? | | |
| | 1) Media Sosial | [1] Ya | [2] Tidak |
| | 2) Televisi | [1] Ya | [2] Tidak |
| | 3) Koran/Majalah | [1] Ya | [2] Tidak |
| | 4) Radio | [1] Ya | [2] Tidak |

| PERSEPSI KERENTANAN YANG DIRASAKAN APABILA TERTULAR COVID-19 | | |
|---|--|--|
| 1 | Peluang saya terkena COVID-19 dalam beberapa bulan ke depan sangat besar | [1] Sangat setuju [2] Setuju [3] Tidak Setuju [4] Sangat Tidak Setuju |
| 2 | Saya khawatir tentang kemungkinan tertular COVID 19 | [1] Sangat setuju [2] Setuju [3] Tidak Setuju [4] Sangat Tidak Setuju |
| 3 | Memungkinkan bagi saya saat ini untuk tertular COVID-19 | [1] Sangat setuju [2] Setuju [3] Tidak Setuju [4] Sangat Tidak Setuju |

| PERSEPSI KEPARAHAN YANG DIRASAKAN APABILA TERTULAR COVID-19 | | |
|--|---|--|
| 1 | Komplikasi dari COVID-19 sangat serius | [1] Sangat setuju [2] Setuju [3] Tidak Setuju [4] Sangat Tidak Setuju |
| 2 | Saya akan sangat sakit jika saya terkena COVID-19 | [1] Sangat setuju [2] Setuju [3] Tidak Setuju [4] Sangat Tidak Setuju |
| 3 | Saya takut tertular COVID-19 | [1] Sangat setuju [2] Setuju [3] Tidak Setuju [4] Sangat Tidak Setuju |

| PERSEPSI MANFAAT YANG DIRASAKAN DARI VAKSINASI COVID-19 | | |
|--|--|---------------------------------|
| 1 | Vaksinasi adalah ide yang bagus karena setelah divaksin, saya merasa tidak terlalu | [1] Sangat setuju [2] Setuju |

| | | |
|---|--|--|
| | khawatir tertular COVID-19 | [3] Tidak Setuju [4] Sangat Tidak Setuju |
| 2 | Vaksinasi mengurangi peluang saya terkena COVID-19 atau komplikasinya | [1] Sangat setuju [2] Setuju [3] Tidak Setuju [4] Sangat Tidak Setuju |
| 3 | Vaksinasi mengurangi peluang saya mengalami gejala yang lebih parah ketika tertular COVID-19 | [1] Sangat setuju [2] Setuju [3] Tidak Setuju [4] Sangat Tidak Setuju |

| G | PENERIMAAN VAKSIN COVID-19 | |
|---|---|---------------------|
| 1 | Jika vaksin COVID-19 tersedia, Apakah Anda bersedia menerima vaksin COVID-19? | [1] Ya [2] Tidak |

| H | PERSEPSI HAMBATAN YANG DIRASAKAN APABILA TERTULAR COVID-19 | |
|---|--|--|
| 1 | Khawatir kemungkinan efek samping vaksinasi COVID-19 akan mengganggu aktivitas saya yang biasa | [1] Sangat setuju [2] Setuju [3] Tidak Setuju [4] Sangat Tidak Setuju |
| 2 | Saya prihatin tentang kemanjuran vaksinasi COVID-19 | [1] Sangat setuju [2] Setuju [3] Tidak Setuju [4] Sangat Tidak Setuju |
| 3 | Saya prihatin tentang keamanan vaksinasi COVID-19 | [1] Sangat setuju [2] Setuju [3] Tidak Setuju [4] Sangat Tidak Setuju |
| 4 | Saya prihatin dengan keterjangkauan saya (biaya vaksin yang tinggi) untuk mendapatkan vaksinasi COVID-19 | [1] Sangat setuju [2] Setuju [3] Tidak Setuju [4] Sangat Tidak Setuju |
| 5 | Saya prihatin dengan vaksin COVID-19 yang salah / palsu | [1] Sangat setuju [2] Setuju [3] Tidak Setuju [4] Sangat Tidak Setuju |

Lampiran 2

MASTER TABEL

Lampiran 3**HASIL ANALISIS DATA****A. Hasil Analisis Univariat****Pengetahuan**

| | Frequency | Percent | Valid Percent | Cumulative Percent |
|--------------|-----------|---------|---------------|--------------------|
| Valid Kurang | 14 | 3.7 | 3.7 | 3.7 |
| Cukup | 367 | 96.3 | 96.3 | 100.0 |
| Total | 381 | 100.0 | 100.0 | |

Kerentanan

| | Frequency | Percent | Valid Percent | Cumulative Percent |
|--------------|-----------|---------|---------------|--------------------|
| Valid Rendah | 233 | 61.2 | 61.2 | 61.2 |
| Tinggi | 148 | 38.8 | 38.8 | 100.0 |
| Total | 381 | 100.0 | 100.0 | |

Keparahan

| | Frequency | Percent | Valid Percent | Cumulative Percent |
|--------------|-----------|---------|---------------|--------------------|
| Valid Rendah | 83 | 21.8 | 21.8 | 21.8 |
| Tinggi | 298 | 78.2 | 78.2 | 100.0 |
| Total | 381 | 100.0 | 100.0 | |

Manfaat

| | Frequency | Percent | Valid Percent | Cumulative Percent |
|--------------|-----------|---------|---------------|--------------------|
| Valid Rendah | 122 | 32.0 | 32.0 | 32.0 |
| Tinggi | 259 | 68.0 | 68.0 | 100.0 |
| Total | 381 | 100.0 | 100.0 | |

Penerimaan Vaksinasi COVID-19

| | Frequency | Percent | Valid Percent | Cumulative Percent |
|----------|-----------|---------|---------------|--------------------|
| Valid Ya | 260 | 68.2 | 68.2 | 68.2 |
| Tidak | 121 | 31.8 | 31.8 | 100.0 |
| Total | 381 | 100.0 | 100.0 | |

Hambatan

| | Frequency | Percent | Valid Percent | Cumulative Percent |
|--------------|-----------|---------|---------------|--------------------|
| Valid Rendah | 79 | 20.7 | 20.7 | 20.7 |
| Tinggi | 302 | 79.3 | 79.3 | 100.0 |
| Total | 381 | 100.0 | 100.0 | |

B. Hasil Analisis Bivariat

Case Processing Summary

| | Cases | | | | | |
|--|-------|-------------|---------|-------------|-------|-------------|
| | Valid | | Missing | | Total | |
| | N | Percen t | N | Percen t | N | Percen t |
| Pengetahuan * Penerimaan Vaksin COVID-19 | 381 | 100.0 % | 0 | 0.0% | 381 | 100.0 % |

Pengetahuan * Penerimaan Vaksin COVID-19 Crosstabulation

| | | Penerimaan Vaksin COVID-19 | | Total |
|-----------------|------------|--|--------|------------------|
| | | 1.0 | 2.0 | |
| Pengetahua n | Kuran g | Count | 18 | 29 |
| | | % within Pengetahuan | 62.1% | 37.9% |
| | | % within Penerimaan Vaksin COVID-19 | 6.9% | 9.1% 7.6% |
| | Cukup | Count | 242 | 352 |
| | | % within Pengetahuan | 68.8% | 31.3% |
| | | % within Penerimaan Vaksin COVID-19 | 93.1% | 90.9% 92.4% |
| Total | | Count | 260 | 381 |
| | | % within Pengetahuan | 68.2% | 31.8% |
| | | % within Penerimaan Vaksin COVID-19 | 100.0% | 100.0% 100.0% |

Chi-Square Tests

| | Value | df | Asymp. Sig. (2- sided) | Exact Sig. (2-sided) | Exact Sig. (1-sided) |
|--------------------|-------------------|----|------------------------------|-------------------------|-------------------------|
| Pearson Chi-Square | .552 ^a | 1 | .458 | | |

| | | | | | |
|------------------------------------|------|---|------|------|------|
| Continuity Correction ^b | .287 | 1 | .592 | | |
| Likelihood Ratio | .536 | 1 | .464 | | |
| Fisher's Exact Test | | | | .534 | .291 |
| Linear-by-Linear Association | .550 | 1 | .458 | | |
| N of Valid Cases | 381 | | | | |

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 9.21.

b. Computed only for a 2x2 table

Case Processing Summary

| | Cases | | | | | |
|-----------------|-------|---------|---------|---------|-------|---------|
| | Valid | | Missing | | Total | |
| | N | Percent | N | Percent | N | Percent |
| Kerentanan * G1 | 381 | 100.0% | 0 | 0.0% | 381 | 100.0% |

Kerentanan * G1 Crosstabulation

| | | G1 | | Total |
|------------|--------|---------------------|--------|--------|
| | | 1 | 2 | |
| Kerentanan | Rendah | Count | 141 | 92 |
| | | % within Kerentanan | 60.5% | 39.5% |
| | | % within G1 | 54.2% | 76.0% |
| | Tinggi | Count | 119 | 29 |
| | | % within Kerentanan | 80.4% | 19.6% |
| | | % within G1 | 45.8% | 24.0% |
| Total | | Count | 260 | 121 |
| | | % within Kerentanan | 68.2% | 31.8% |
| | | % within G1 | 100.0% | 100.0% |

Chi-Square Tests

| | Value | df | Asymp. Sig. (2-sided) | Exact Sig. (2-sided) | Exact Sig. (1-sided) |
|--------------------|---------------------|----|-----------------------|----------------------|----------------------|
| Pearson Chi-Square | 16.522 ^a | 1 | .000 | | |

| | | | | | | |
|------------------------------------|--------|---|------|------|--|------|
| Continuity Correction ^b | 15.617 | 1 | .000 | | | |
| Likelihood Ratio | 17.213 | 1 | .000 | | | |
| Fisher's Exact Test | | | | .000 | | .000 |
| Linear-by-Linear Association | 16.479 | 1 | .000 | | | |
| N of Valid Cases | 381 | | | | | |

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 47.00.

b. Computed only for a 2x2 table

Case Processing Summary

| | Cases | | | | | |
|----------------|-------|---------|---------|---------|-------|---------|
| | Valid | | Missing | | Total | |
| | N | Percent | N | Percent | N | Percent |
| Keparahan * G1 | 381 | 100.0% | 0 | 0.0% | 381 | 100.0% |

Keparahan * G1 Crosstabulation

| | | G1 | | Total |
|-----------|--------|--------------------|--------|--------|
| | | 1 | 2 | |
| Keparahan | Rendah | Count | 32 | 51 |
| | | % within Keparahan | 38.6% | 61.4% |
| | | % within G1 | 12.3% | 42.1% |
| | Tinggi | Count | 228 | 70 |
| | | % within Keparahan | 76.5% | 23.5% |
| | | % within G1 | 87.7% | 57.9% |
| Total | | Count | 260 | 121 |
| | | % within Keparahan | 68.2% | 31.8% |
| | | % within G1 | 100.0% | 100.0% |

Chi-Square Tests

| | Value | df | Asymp. Sig. (2-sided) | Exact Sig. (2-sided) | Exact Sig. (1-sided) |
|--------------------|---------------------|----|-----------------------|----------------------|----------------------|
| Pearson Chi-Square | 43.154 ^a | 1 | .000 | | |

| | | | | | |
|------------------------------------|--------|---|------|------|------|
| Continuity Correction ^b | 41.420 | 1 | .000 | | |
| Likelihood Ratio | 40.706 | 1 | .000 | | |
| Fisher's Exact Test | | | | .000 | .000 |
| Linear-by-Linear Association | 43.040 | 1 | .000 | | |
| N of Valid Cases | 381 | | | | |

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 26.36.

b. Computed only for a 2x2 table

Case Processing Summary

| | Cases | | | | | |
|--------------|-------|---------|---------|---------|-------|---------|
| | Valid | | Missing | | Total | |
| | N | Percent | N | Percent | N | Percent |
| Manfaat * G1 | 381 | 100.0% | 0 | 0.0% | 381 | 100.0% |

Manfaat * Penerimaan Vaksin COVID-19 Crosstabulation

| | | | Penerimaan Vaksin COVID-19 | | Total |
|---------|--------|-------------------------------------|----------------------------|------------------|--------|
| | | | 1.0 | 2.0 | |
| | | | Count | % within Manfaat | |
| Manfaat | Rendah | Count | 46 | 75 | 121 |
| | | % within Manfaat | 38.0% | 62.0% | 100.0% |
| | | % within Penerimaan Vaksin COVID-19 | 17.7% | 62.0% | 31.8% |
| | Tinggi | Count | 214 | 46 | 260 |
| | | % within Manfaat | 82.3% | 17.7% | 100.0% |
| | | % within Penerimaan Vaksin COVID-19 | 82.3% | 38.0% | 68.2% |
| Total | | Count | 260 | 121 | 381 |
| | | % within Manfaat | 68.2% | 31.8% | 100.0% |
| | | % within Penerimaan Vaksin COVID-19 | 100.0% | 100.0% | 100.0% |

Chi-Square Tests

| | Value | df | Asymp. Sig. (2-sided) | Exact Sig. (2-sided) | Exact Sig. (1-sided) |
|--------------------|---------------------|----|-----------------------|----------------------|----------------------|
| Pearson Chi-Square | 74.741 ^a | 1 | .000 | | |

| | | | | | |
|------------------------------------|--------|---|------|------|------|
| Continuity Correction ^b | 72.711 | 1 | .000 | | |
| Likelihood Ratio | 72.873 | 1 | .000 | | |
| Fisher's Exact Test | | | | .000 | .000 |
| Linear-by-Linear Association | 74.545 | 1 | .000 | | |
| N of Valid Cases | 381 | | | | |

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 38.43.

b. Computed only for a 2x2 table

Case Processing Summary

| | Cases | | | | | |
|---------------|-------|---------|---------|---------|-------|---------|
| | Valid | | Missing | | Total | |
| | N | Percent | N | Percent | N | Percent |
| Hambatan * G1 | 381 | 100.0% | 0 | 0.0% | 381 | 100.0% |

Hambatan * G1 Crosstabulation

| | | | G1 | | Total |
|----------|--------|-------------------|--------|--------|--------|
| | | | 1 | 2 | |
| Hambatan | Rendah | Count | 66 | 13 | 79 |
| | | % within Hambatan | 83.5% | 16.5% | 100.0% |
| | | % within G1 | 25.4% | 10.7% | 20.7% |
| | Tinggi | Count | 194 | 108 | 302 |
| | | % within Hambatan | 64.2% | 35.8% | 100.0% |
| | | % within G1 | 74.6% | 89.3% | 79.3% |
| Total | | Count | 260 | 121 | 381 |
| | | % within Hambatan | 68.2% | 31.8% | 100.0% |
| | | % within G1 | 100.0% | 100.0% | 100.0% |

Chi-Square Tests

| | Value | df | Asymp. Sig. (2-sided) | Exact Sig. (2-sided) | Exact Sig. (1-sided) |
|------------------------------------|---------------------|----|-----------------------|----------------------|----------------------|
| Pearson Chi-Square | 10.769 ^a | 1 | .001 | | |
| Continuity Correction ^b | 9.897 | 1 | .002 | | |
| Likelihood Ratio | 11.799 | 1 | .001 | | |

| | | | | | |
|------------------------------|--------|---|------|------|------|
| Fisher's Exact Test | | | | .001 | .001 |
| Linear-by-Linear Association | 10.741 | 1 | .001 | | |
| N of Valid Cases | 381 | | | | |

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 25.09.

b. Computed only for a 2x2 table

Ket:

G1 = Penerimaan Vaksin COVID-19

Case Processing Summary

| | Cases | | | | | |
|---------------|-------|---------|---------|---------|-------|---------|
| | Valid | | Missing | | Total | |
| | N | Percent | N | Percent | N | Percent |
| B1 * G1 | 381 | 100.0% | 0 | 0.0% | 381 | 100.0% |

B1 * G1 Crosstabulation

| | | | G1 | | Total |
|----|-----------|----------------|--------|--------|--------|
| | | | 1.0 | 2.0 | |
| B1 | Perempuan | Count | 197 | 83 | 280 |
| | | % within B1 | 70.4% | 29.6% | 100.0% |
| | | % within G1 | 75.8% | 68.6% | 73.5% |
| | Laki-Laki | Count | 63 | 38 | 101 |
| | | % within B1 | 62.4% | 37.6% | 100.0% |
| | | % within G1 | 24.2% | 31.4% | 26.5% |
| | Total | Count | 260 | 121 | 381 |
| | | % within B1 | 68.2% | 31.8% | 100.0% |
| | | % within G1 | 100.0% | 100.0% | 100.0% |

Chi-Square Tests

| | Value | df | Asymp. Sig. (2-sided) | Exact Sig. (2-sided) | Exact Sig. (1-sided) |
|--|-------|----|--------------------------|-------------------------|-------------------------|
| | | | | | |

| | | | | | | |
|------------------------------------|--------------------|---|------|------|--|------|
| Pearson Chi-Square | 2.181 ^a | 1 | .140 | | | |
| Continuity Correction ^b | 1.829 | 1 | .176 | | | |
| Likelihood Ratio | 2.142 | 1 | .143 | | | |
| Fisher's Exact Test | | | | .170 | | .089 |
| Linear-by-Linear Association | 2.176 | 1 | .140 | | | |
| N of Valid Cases | 381 | | | | | |

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 32.08.

b. Computed only for a 2x2 table

Case Processing Summary

| | Cases | | | | | |
|--------------|-------|---------|---------|---------|-------|---------|
| | Valid | | Missing | | Total | |
| | N | Percent | N | Percent | N | Percent |
| Kerentanan * | 381 | 100.0% | 0 | 0.0% | 381 | 100.0% |
| Pengetahuan | | | | | | |

Kerentanan * Pengetahuan Crosstabulation

| | | | Pengetahuan | | Total |
|------------|--------|----------------------|-------------|--------|--------|
| | | | Kurang | Cukup | |
| Kerentanan | Rendah | Count | 12 | 221 | 233 |
| | | % within Kerentanan | 5.2% | 94.8% | 100.0% |
| | | % within Pengetahuan | 41.4% | 62.8% | 61.2% |
| | Tinggi | Count | 17 | 131 | 148 |
| | | % within Kerentanan | 11.5% | 88.5% | 100.0% |
| | | % within Pengetahuan | 58.6% | 37.2% | 38.8% |
| | Total | Count | 29 | 352 | 381 |
| | | % within Kerentanan | 7.6% | 92.4% | 100.0% |
| | | % within Pengetahuan | 100.0% | 100.0% | 100.0% |

Chi-Square Tests

| | Value | df | Asymp. Sig. (2-sided) | Exact Sig. (2-sided) | Exact Sig. (1-sided) |
|--------------------|--------------------|----|-----------------------|----------------------|----------------------|
| Pearson Chi-Square | 5.167 ^a | 1 | .023 | | |

| | | | | | |
|------------------------------------|-------|---|------|------|------|
| Continuity Correction ^b | 4.306 | 1 | .038 | | |
| Likelihood Ratio | 5.011 | 1 | .025 | | |
| Fisher's Exact Test | | | | .029 | .020 |
| Linear-by-Linear Association | 5.154 | 1 | .023 | | |
| N of Valid Cases | 381 | | | | |

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 11.27.

b. Computed only for a 2x2 table

Case Processing Summary

| | Cases | | | | | |
|-------------|-------|---------|---------|---------|-------|---------|
| | Valid | | Missing | | Total | |
| | N | Percent | N | Percent | N | Percent |
| Keparahan * | 381 | 100.0% | 0 | 0.0% | 381 | 100.0% |
| Pengetahuan | | | | | | |

Keparahan * Pengetahuan Crosstabulation

| | | | Pengetahuan | | Total |
|-------------|--------|----------------------|-------------|--------|--------|
| | | | Kurang | Cukup | |
| Keparahan * | Rendah | Count | 2 | 81 | 83 |
| | | % within Keparahan | 2.4% | 97.6% | 100.0% |
| | | % within Pengetahuan | 6.9% | 23.0% | 21.8% |
| | Tinggi | Count | 27 | 271 | 298 |
| | | % within Keparahan | 9.1% | 90.9% | 100.0% |
| | | % within Pengetahuan | 93.1% | 77.0% | 78.2% |
| Total | | Count | 29 | 352 | 381 |
| | | % within Keparahan | 7.6% | 92.4% | 100.0% |
| | | % within Pengetahuan | 100.0% | 100.0% | 100.0% |

Chi-Square Tests

| | Value | df | Asymp. Sig. (2-sided) | Exact Sig. (2-sided) | Exact Sig. (1-sided) |
|--------------------|--------------------|----|-----------------------|----------------------|----------------------|
| Pearson Chi-Square | 4.083 ^a | 1 | .043 | | |

| | | | | | |
|------------------------------------|-------|---|------|------|------|
| Continuity Correction ^b | 3.192 | 1 | .074 | | |
| Likelihood Ratio | 5.115 | 1 | .024 | | |
| Fisher's Exact Test | | | | .058 | .028 |
| Linear-by-Linear Association | 4.073 | 1 | .044 | | |
| N of Valid Cases | 381 | | | | |

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 6.32.

b. Computed only for a 2x2 table

Case Processing Summary

| | Cases | | | | | |
|-----------------------|-------|---------|---------|---------|-------|---------|
| | Valid | | Missing | | Total | |
| | N | Percent | N | Percent | N | Percent |
| Manfaat * Pengetahuan | 381 | 100.0% | 0 | 0.0% | 381 | 100.0% |

Manfaat * Pengetahuan Crosstabulation

| | | | Pengetahuan | | Total |
|-----------------|--------|-------------------------|-------------|--------|--------|
| | | | Kurang | Cukup | |
| Ma nfa at | Rendah | Count | 4 | 117 | 121 |
| | | % within Manfaat | 3.3% | 96.7% | 100.0% |
| | | % within Pengetahuan | 13.8% | 33.2% | 31.8% |
| | Tinggi | Count | 25 | 235 | 260 |
| | | % within Manfaat | 9.6% | 90.4% | 100.0% |
| | | % within Pengetahuan | 86.2% | 66.8% | 68.2% |
| Total | | Count | 29 | 352 | 381 |
| | | % within Manfaat | 7.6% | 92.4% | 100.0% |
| | | % within Pengetahuan | 100.0% | 100.0% | 100.0% |

Chi-Square Tests

| | Value | df | Asymp. Sig. (2-sided) | Exact Sig. (2- sided) | Exact Sig. (1-sided) |
|------------------------------------|--------------------|----|--------------------------|-----------------------------|-------------------------|
| Pearson Chi-Square | 4.675 ^a | 1 | .031 | | |
| Continuity Correction ^b | 3.820 | 1 | .051 | | |

| | | | | | |
|------------------------------|-------|---|------|------|------|
| Likelihood Ratio | 5.366 | 1 | .021 | .037 | .020 |
| Fisher's Exact Test | | | | | |
| Linear-by-Linear Association | 4.662 | 1 | .031 | | |

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 9.21.

b. Computed only for a 2x2 table

Case Processing Summary

| | Cases | | | | | |
|------------------------|-------|---------|---------|---------|-------|---------|
| | Valid | | Missing | | Total | |
| | N | Percent | N | Percent | N | Percent |
| Hambatan * Pengetahuan | 381 | 100.0% | 0 | 0.0% | 381 | 100.0 % |

Hambatan * Pengetahuan Crosstabulation

| | | Pengetahuan | | Total |
|----------|--------|----------------------|--------|--------|
| | | Kurang | Cukup | |
| Hambatan | Rendah | Count | 5 | 79 |
| | | % within Hambatan | 6.3% | 93.7% |
| | | % within Pengetahuan | 17.2% | 21.0% |
| Tinggi | | Count | 24 | 302 |
| | | % within Hambatan | 7.9% | 92.1% |
| | | % within Pengetahuan | 82.8% | 79.0% |
| Total | | Count | 29 | 352 |
| | | % within Hambatan | 7.6% | 92.4% |
| | | % within Pengetahuan | 100.0% | 100.0% |

Chi-Square Tests

| | Value | df | Asymp. Sig. (2-sided) | Exact Sig. (2-sided) | Exact Sig. (1-sided) |
|------------------------------------|-------------------|----|-----------------------|----------------------|----------------------|
| Pearson Chi-Square | .233 ^a | 1 | .629 | | |
| Continuity Correction ^b | .060 | 1 | .807 | | |
| Likelihood Ratio | .243 | 1 | .622 | | |

| | | | | | |
|------------------------------|------|---|------|------|------|
| Fisher's Exact Test | | | | .813 | .419 |
| Linear-by-Linear Association | .232 | 1 | .630 | | |
| N of Valid Cases | 381 | | | | |

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 6.01.

b. Computed only for a 2x2 table

Lampiran 4

PERSURATAN



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN,
RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN
FAKULTAS KESEHATAN MASYARAKAT
Jalan Perintis Kemerdekaan Km. 10 Makassar 90245, Telp. (0411) 585658
E-mail : fkm.unhas@gmail.com, Website : fkm.unhas.ac.id

Nomor : 7090/UN4.14.8/PT.01.04/2021
Perihal : Permohonan Izin Penelitian

16 Agustus 2021


Yang Terhormat
Kepala Dinas Penanaman Modal dan Pelayanan Satu Pintu
Cq. Bidang Penyelenggara Pelayanan Perizinan
Provinsi Sulawesi Selatan
di-Makassar

Dengan hormat, Kami sampaikan bahwa mahasiswa Fakultas Kesehatan Masyarakat Universitas Hasanuddin bermaksud untuk melakukan penelitian dalam rangka penyusunan skripsi.

Sehubungan dengan itu, kami mohon kiranya bantuan Bapak dapat memberikan izin untuk penelitian kepada:

Nama Mahasiswa : Deby Karmila Musakkhar
Stambuk : K011171047
Program Studi : Kesehatan Masyarakat
Departemen : Epidemiologi
Judul Penelitian : Faktor Yang Berhubungan Dengan Penerimaan Vaksin COVID-19 Pada Remaja Usia 18-24 Tahun di Kota Palopo Tahun 2021
Lokasi Penelitian : Kota Palopo
Pembimbing Skripsi : 1. Ansariadi, SKM, M.ScPH, Ph.D
2. Dr. Wahiduddin, S.KM, M.Kes

Atas bantuan dan kerjasama yang baik, kami sampaikan banyak terima kasih.



Tembusan:

1. Dekan FKM Unhas sebagai laporan
2. Para Pembimbing Skripsi



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN

RISET, DAN TEKNOLOGI

UNIVERSITAS HASANUDDIN

FAKULTAS KESEHATAN MASYARAKAT

Jln.Perintis Kemerdekaan Km.10 Makassar 90245, Telp.(0411) 585658,

E-mail : fkm.unhas@gmail.com, website: <https://fkm.unhas.ac.id/>

REKOMENDASI PERSETUJUAN ETIK

Nomor : **8074/UN4.14.1/TP.01.02/2021**

Tanggal : 14 September 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

| | | | |
|-----------------------------------|--|---|---|
| No.Protokol | 17821052111 | No. Sponsor Protokol | |
| Peneliti Utama | Deby Karmila Musakkar | Sponsor | Pribadi |
| Judul Peneliti | Faktor-Faktor yang Berhubungan dengan Penerimaan Vaksin COVID-19 pada Remaja Usia 18-24 Tahun di Kota Palopo Tahun 2021 | | |
| No.Versi Protokol | 1 | Tanggal Versi | 17 Agustus 2021 |
| No.Versi PSP | 1 | Tanggal Versi | 17 Agustus 2021 |
| Tempat Penelitian | Kota Palopo | | |
| Judul Review | <input checked="" type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input type="checkbox"/> Fullboard | Masa Berlaku 14 September 2021 Sampai 14 September 2022 | Frekuensi review lanjutan |
| Ketua Komisi Etik Penelitian | Nama : Prof.dr. Veni Hadju,M.Sc,Ph.D | Tanda tangan |  Tanggals 14 September 2021 |
| Sekretaris komisi Etik Penelitian | Nama : Dr. Wahiduddin, SKM.,M.Kes | Tanda tangan |  Tanggals 14 September 2021 |

Kewajiban Peneliti Utama :

1. Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
2. Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
3. Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
4. Menyerahkan laporan akhir setelah Penelitian berakhir
5. Melaporkan penyimpangan dari protocol yang disetujui (protocol deviation/violation)
6. Mematuhi semua peraturan yang ditentukan



1 2 0 2 1 1 9 0 0 9 0 6 4 2

PEMERINTAH KOTA PALOPO
DINAS PENANAMAN MODAL DAN PELAYANAN TERPADU SATU PINTU

Alamat : Jl. K.H.M. Hasyim No.5 Kota Palopo - Sulawesi Selatan Telpn : (0471) 328048

ASLI

DASAR HUKUM :

- Undang-Undang Nomor 11 Tahun 2019 tentang Sistem Nasional Ilmu Pengetahuan dan Teknologi;
- Undang-Undang Nomor 11 Tahun 2020 tentang Cipta Kerja;
- Peraturan Mendagri Nomor 3 Tahun 28 tentang Penerbitan Surat Keterangan Penelitian;
- Peraturan Walikota Palopo Nomor 23 Tahun 2016 tentang Pernyderhanan Perizinan dan Non Perizinan di Kota Palopo;
- Peraturan Walikota Palopo Nomor 34 Tahun 2019 tentang Pendlegasian Kewenangan Penyelenggaraan Perizinan dan Nonperizinan Yang Menjadi Urusan Pemerintah Kota Palopo dan Kewenangan Perizinan dan Nonperizinan Yang Menjadi Urusan Pemerintah Yang Diberikan Pelimpahan Wewenang Walikota Palopo Kepada Dinas Penanaman Modal dan Pelayanan Terpadu Satu Pintu Kota Palopo.

IZIN PENELITIAN

NOMOR : 642/IP/DPMPTSP/I/X/2021

MEMBERIKAN IZIN KEPADA

| | |
|---------------|--|
| Nama | : DEBY KARMILA MUSAKKAR |
| Jenis Kelamin | : Perempuan |
| Alamat | : Perum. Surutanga Reciden Blok D 12 Kota Palopo |
| Pekerjaan | : Mahasiswa |
| NIM | : K0111171047 |

Maksud dan Tujuan mengadakan penelitian dalam rangka penulisan Skripsi dengan Judul :

**FAKTOR YANG BERHUBUNGAN DENGAN PENERIMAAN VAKSIN COVID-19 PADA REMAJA USIA 18-24
TAHUN DI KOTA PALOPO TAHUN 2021**

| | |
|--------------------|---|
| Lokasi Penelitian | : KANTOR WALIKOTA PALOPO |
| Lamanya Penelitian | : 09 September 2021 s.d. 09 November 2021 |

DENGAN KETENTUAN SEBAGAI BERIKUT :

- Sebelum dan sesudah melaksanakan kegiatan penelitian kiranya melapor pada Dinas Penanaman Modal dan Pelayanan Terpadu Satu Pintu Kota Palopo.
- Menaaati semua peraturan perundang-undangan yang berlaku, serta menghormati Adat Istiadat setempat.
- Penelitian tidak menyimpang dari maksud izin yang diberikan.
- Menyerahkan 1 (satu) exemplar foto copy hasil penelitian kepada Dinas Penanaman Modal dan Pelayanan Terpadu Satu Pintu Kota Palopo.
- Surat Izin Penelitian ini dinyatakan tidak berlaku, bila mana pemegang izin ternyata tidak menaati ketentuan tersebut di atas.

Demikian Surat Izin Penelitian ini diterbitkan untuk dipergunakan sebagaimana mestinya.

Diterbitkan di Kota Palopo
Pada tanggal : 09 September 2021
pt. Kepala Dinas Penanaman Modal dan PTSP

MUH. IHSAN ASHARUDDIN, S.STP, M.SI
Pangkat : Pembina Tk.I
NIP : 19780611 199612 1 001

Tembusan :

- Kepala Badan Kesbang Prov. Sul-Sel.
- Walikota Palopo
- Dandim 1403 SWL
- Kapolda Palopo
- Kepala Badan Penelitian dan Pengembangan Kota Palopo
- Kepala Badan Kesbang Kota Palopo
- Industri teritorial yang dilaksanakan penelitian

Lampiran 5

RIWAYAT HIDUP



A. IDENTITAS

Nama : Deby Karmila Musakkar
Tempat/Tanggal Lahir : Palopo, 02 Desember 1998
Jenis Kelamin : Perempuan
Agama : Islam
Alamat : Perum. Reciden Surutanga Blok D.12, Kota Palopo
Email : debykarmila02@gmail.com
No. Hp : 085349169135
Nama Orang Tua : Musakkar & Ilawati Yamin

B. RIWAYAT PENDIDIKAN

7. TK : TK Tunas Bangsa Kota Baru, tahun 2005
8. SD : SDN Sang-Sang Kota Baru, tahun 2011
9. SMP : MTsN Model Palopo, tahun 2014
10. SMA : SMA Negeri 3 Palopo, tahun 2017
11. Perguruan Tinggi : Program Sarjana Program Studi Kesehatan Masyarakat, Fakultas Kesehatan Masyarakat Universitas Hasanuddin Makassar, Tahun masuk 2017.

C. RIWAYAT ORGANISASI

1. Lembaga Dakwah Al-‘Aafiyah Fakultas Kesehatan Masyarakat Universitas Hasanuddin Tahun 2019-2021.
2. UKM LDK MPM Universitas Hasanuddin Tahun 2020-2021
3. Himpunan Mahasiswa Epidemiologi Fakultas Kesehatan Masyarakat Universitas Hasanuddin Tahun 2020-2021.